International Journal of Cancer Management

Published by: Kowsar

Topical Calcineurin Inhibitors and Malignancy Risk

Tamara Cuk Radovic 1 , * , Kresimir Kostovic 2 , Romana Ceovic 2 and Zrinka Bukvic Mokos 2
Authors Information
1 Poliklinika Nola, Zagreb, Croatia
2 Department of Dermatovenereology, University Hospital Center Zagreb and School of Medicine University of Zagreb, Zagreb, Croatia
Article information
  • International Journal of Cancer Management: April 2017, 10 (4); e6173
  • Published Online: March 20, 2017
  • Article Type: Review Article
  • Received: March 30, 2016
  • Revised: September 17, 2016
  • Accepted: March 13, 2016
  • DOI: 10.5812/ijcm.6173

To Cite: Radovic T C, Kostovic K, Ceovic R, Mokos Z B. Topical Calcineurin Inhibitors and Malignancy Risk, Int J Cancer Manag. 2017 ; 10(4):e6173. doi: 10.5812/ijcm.6173.

Abstract
Copyright © 2017, International Journal of Cancer Management. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Protopic (Tacrolimus) ointment 0.03 % and ointment 0.1 % (US prescribing information). Deerfield (IL): Fujisawa Healthcare, Inc. 2000;
  • 2. Elidel (Pimecrolimus) cream 1% (US prescribing information).
  • 3. Arai T, Kouama Y, Suenaga T, Honda H. Ascomycin, an antifungal antibiotic. J Antibiot (Tokyo). 1962; 15: 231-2[PubMed]
  • 4. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg. 2001; 20(4): 233-41[DOI][PubMed]
  • 5. Stuetz A, Baumann K, Grassberger M, Wolff K, Meingassner JG. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol. 2006; 141(3): 199-212[DOI][PubMed]
  • 6. Czarnecka-Operacz M, Jenerowicz D. Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues. J Dtsch Dermatol Ges. 2012; 10(3): 167-72[DOI][PubMed]
  • 7. Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs. 2013; 15(4): 303-10[DOI][PubMed]
  • 8. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006; 54(1): 1-15[DOI][PubMed]
  • 9. Manthripragada AD, Pinheiro SP, MaCurdy TE, Saneinejad S, Worrall CM, Kelman JA, et al. Off-label topical calcineurin inhibitor use in children. Pediatrics. 2013; 132(5)-32[DOI][PubMed]
  • 10. Briefing document from Patty Greene, Drug Use Data Analyst, Division of Epidemiology, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. BPCA drug use review: Comparison of Elidel_ cream and Protopic ointment utilization trends following 2006 labeling changes, 17 July. 2009;
  • 11. Thaci D, Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol. 2010; 28(1): 52-6[DOI][PubMed]
  • 12. Novartis , Fujisawa . FDA briefing statements. Pediatric Advisory Committee Meeting of the US Food and Drug Administration. 2005;
  • 13. Ceilley R, Eisenthal A. The unintended effects of a boxed warning. J Clin Aesthet Dermatol. 2009; 2(9): 33-9[PubMed]
  • 14. Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin. 2008; 24(4): 985-94[DOI][PubMed]
  • 15. Fonacier L, Spergel J, Charlesworth EN, Weldon D, Beltrani V, Bernhisel-Broadbent J, et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2005; 115(6): 1249-53[DOI][PubMed]
  • 16. American Academy of Dermatology issues statement in response to FDA decision related to two eczema medications (news release). American Academy of Dermatology (AAD). 20 Mar 2005;
  • 17. Canadian Dermatology Association (CDA) . Position Statement on Topical Calcineurin Inhibitors (media release). 2005;
  • 18. Segal AO, Ellis AK, Kim HL. CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy Asthma Clin Immunol. 2013; 9(1): 24[DOI][PubMed]
  • 19. Briefing document from Angelika Manthripragada, Epidemiologist, Division of Epidemiology, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Calcineurin inhibitor pediatric literature review. 23 Sep 2010;
  • 20. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology. 2007; 214(4): 289-95[DOI][PubMed]
  • 21. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007; 127(4): 808-16[DOI][PubMed]
  • 22. Arellano FM, Arana A, Wentworth CE, Fernandez-Vidaurre C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol. 2009; 123(5): 1111-6[DOI][PubMed]
  • 23. Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother. 2009; 43(12): 1956-63[DOI][PubMed]
  • 24. Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology. 2009; 219(1): 7-21[DOI][PubMed]
  • 25. Arana A, Wentworth CW, Rivero E, Plana E, Conde E. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids and/or topical calcineurin inhibitors. J Am Acad Dermatol. 2011; 64(2 Suppl 1)
  • 26. Arana A, Wentworth CW, Rivero E, Plana E, Conde E. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCIs). Pharmacoepidemiol Drug Saf. 2010; 19: 12
  • 27. Briefing document from Angelika Manthripragada, Epidemiologist, Division of Epidemiology, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Addendum: update on calcineurin inhibitor pediatric literature review. 10 May 2011;
  • 28. Briefing document from Namita Kothary, Safety Evaluator, Division of Pharmacovigilance I, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Update on Malignancies in Children. 4 Apr 2011;
  • 29. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol. 2005; 125(5): 1020-5[DOI][PubMed]
  • 30. Food and Drug Administration. Novartis Elidel (pimecrolimus) cream 1% briefing document. 2006;
  • 31. Food and Drug Administration. Astellas Pharma (tacrolimus) ointment 0,03% and 0,1% briefing document. 2006;
  • 32. Papp KA, Breuer K, Meurer M, Ortonne JP, Potter PC, de Prost Y, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol. 2005; 52(2): 247-53[DOI][PubMed]
  • 33. Stiehm ER, Roberts RL, Kaplan MS, Corren J, Jaracz E, Rico MJ. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol. 2005; 53(2 Suppl 2)-13[DOI][PubMed]
  • 34. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002; 110(1 Pt 1)[DOI][PubMed]
  • 35. Ellingsen AR, Sorensen FB, Larsen JO, Deleuran MS, Thestrup-Pedersen K. Stereological quantification of lymphocytes in skin biopsies from atopic dermatitis patients. Acta Derm Venereol. 2001; 81(4): 258-62[PubMed]
  • 36. Sanchez-Perez J. [Topical pimecrolimus and tacrolimus and the risk of cancer]. Actas Dermosifiliogr. 2007; 98(5): 312-7[DOI][PubMed]
  • 37. Orlow SJ. Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues. Paediatr Drugs. 2007; 9(5): 289-99[DOI][PubMed]
  • 38. Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep. 2006; 6(4): 270-4[DOI][PubMed]
  • 39. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010; 105(2): 99-106[DOI][PubMed]
  • 40. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014; 70(2): 338-51[DOI][PubMed]
  • 41. Charman C. Clinical evidence: atopic eczema. BMJ. 1999; 318(7198): 1600-4[DOI][PubMed]
  • 42. Tollefson MM, Bruckner AL, Section On D. Atopic dermatitis: skin-directed management. Pediatrics. 2014; 134(6)-44[DOI][PubMed]
  • 43. Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. J Am Acad Dermatol. 2015; 72(6): 992-1002[DOI][PubMed]
  • 44. Arana A, Wentworth CE, Fernandez-Vidaurre C, Schlienger RG, Conde E, Arellano FM. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol. 2010; 163(5): 1036-43[DOI][PubMed]
  • 45. Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001; 137(6): 778-83[PubMed]
  • 46. Soderberg KC, Hagmar L, Schwartzbaum J, Feychting M. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health. 2004; 4: 51[DOI][PubMed]
  • 47. Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013; 14(3): 163-78[DOI][PubMed]
  • 48. Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol. 2011; 165(3): 465-73[DOI][PubMed]
  • 49. Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D, Bilker WB. Association Between Malignancy and Topical Use of Pimecrolimus. JAMA Dermatol. 2015; 151(6): 594-9[DOI][PubMed]
  • 50. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol. 2005; 153(4): 701-5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments